Buy Three, Get the Fourth Free! | Start Saving >>
Activators & Inhibitors

Sorafenib #8705

Western Blotting

Western blot analysis of extracts from NIH/3T3 cells, serum-starved overnight and untreated or treated with hPDGF-BB #8912 (100 ng/ml, 5 min) either with or without sorafenib pre-treatment (1 µM, 2 hr), using Phospho-PDGF Receptor β (Tyr1009) (42F9) Rabbit mAb #3124 (upper) or PDGF Receptor β (28E1) Rabbit mAb #3169 (lower).

Learn more about how we get our images

Chemical structure of sorafenib.

Learn more about how we get our images

Sorafenib is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 10 mg in 1.57 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used as a pretreatment at 0.1-10 µM for 0.5-2 hr prior to treating with a stimulator. It can also be used alone, with varying treatment times lasting up to 24 hr. Soluble in DMSO at 200 mg/ml; very poorly soluble in ethanol and water with maximum solubility in water ~10-20 µM.


Store lyophilized or in solution at -20ºC. In lyophlized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency.

Molecular Weight:

637.03 g/mol



Molecular Formula:

C21H16ClF3N4O3 • C7H8O3S

Sorafenib, also known as Bay 43-9006, is a novel multikinase inhibitor that targets the RAF family of serine/threonine kinases and tyrosine kinase receptors involved in tumor progression and tumor angiogenesis, including: VEGFR-2 (IC50 = 90 nM), VEGFR-3 (IC50 = 20 nM), PDGFR- (IC50 = 57 nM), c-KIT (IC50 = 68 nM), and Flt3 (IC50 = 58 nM) (1). Research studies have demonstrated that sorafenib induces apoptosis in several tumor cell lines through the down-regulation of the antiapoptotic protein myeloid cell leukemia-1 (Mcl-1). Down-regulation of Mcl-1 by sorafenib is associated with the release of cytochrome c from mitochondria into the cytosol and caspase activation, leading to apoptotic cell death (2). STAT3 inhibition by sorafenib has been observed in multiple cell types (3-5).

  1. Wilhelm, S.M. et al. (2004) Cancer Res 64, 7099-109.
  2. Yu, C. et al. (2005) Oncogene 24, 6861-9.
  3. Zhao, W. et al. (2011) Anticancer Drugs 22, 79-88.
  4. Huang, S. and Sinicrope, F.A. (2010) Mol Cancer Ther 9, 742-50.
  5. Yang, F. et al. (2008) Mol Cancer Ther 7, 3519-26.
For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.


To Purchase # 8705S

View sizes
Product # Size Price
10 mg $ 113.0